Open AccessTreatment options to COVID-19
Author(s) -
Claudia Cristina de Aguiar Pereira,
Lenita Lima,
Ana Alice Amaral Ibiapina Parente,
Maria de Fátima Sant ́Anna
Publication year - 2020
Publication title -
residência pediátrica
Language(s) - English
Resource type - Journals
ISSN - 2236-6814
DOI - 10.25060/residpediatr-2020.v10n3-363
Subject(s) - hydroxychloroquine , tocilizumab , medicine , azithromycin , covid-19 , chloroquine , pharmacology , angiotensin receptor blockers , coronavirus , intensive care medicine , virology , renin–angiotensin system , immunology , malaria , biology , outbreak , rheumatoid arthritis , antibiotics , disease , blood pressure , infectious disease (medical specialty) , microbiology and biotechnology
Still today, there is no specific therapy or COVID-19 and vaccines under study are not yet available. The following document contain therapeutic options suggested with basis in available information, until the date, in several studies with experimental treatment approaches. There were included studies with antiviral drugs, chloroquine, hydroxychloroquine, azithromycin, tocilizumab, vitamin D, anticoagulation, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), beta interferon, convalescent plasma and corticosteroids. It was concluded that, although some promising drugs had showed action, in vitro, to date, none therapy was actually safe and secure against the novel coronavirus in humans.